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Osmotic demyelination syndrome is a devastating neurologic
disorder often seen after the rapid correction of chronic
hyponatremia. The permeability of the blood–brain barrier is
increased in experimental osmotic demyelination, and some
have suggested that corticosteroids protect against this
disorder by keeping the permeability of the blood–brain
barrier low. We previously reported that re-lowering of the
serum sodium after rapid correction of chronic hyponatremia
was beneficial if performed early in the course (12 to 24h).
Here we compared mortality, blood–brain barrier
permeability, and microglial activation in rats after the
rapid correction of chronic hyponatremia. We studied three
groups of rats after correction of chronic hyponatremia:
and treated them with sodium chloride, with or without
dexamethasone; or with sodium chloride followed by
re-induction of hyponatremia. We found that treatment with
dexamethasone or re-induction of hyponatremia effectively
prevented the opening of the blood–brain barrier, reduced
neurological manifestations, and decreased microglial
activation; however, only re-induction of hyponatremia
resulted in a significant decrease in mortality 5 days after the
correction of chronic hyponatremia. Restoring the
permeability of the blood–brain barrier to normal levels did
not decrease mortality. Our results suggest that after
inadvertent rapid correction of hyponatremia, treatment
options should favor re-lowering serum sodium. The
increased permeability of blood–brain barrier seen in osmotic
demyelination syndrome may not be a primary
pathophysiologic insult of this syndrome.
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Osmotic demyelination syndrome (ODS) occurs after excessive
correction of chronic hyponatremia.1,2 Histological lesions
consist of symmetrical foci of demyelination, with activated
microglia infiltration in different regions of the brain.1,2 The
physiopathology of this condition is poorly understood, and as
a result, very few interventions have been reported to be
beneficial in ODS.3,4 The development of ODS lesions probably
involves complex interactions among blood–brain barrier
(BBB), brain organic osmolyte fluxes, microglia, and inflam-
matory cytokines.4 The permeability of BBB in experimental
ODS has been previously investigated and some have
postulated that the opening of the BBB, provoked by a rapid
correction of chronic hyponatremia, could result in the
exposure of the brain to myelinolytic substances and subse-
quently induce ODS lesions.5–7 It has recently been suggested
that the administration of corticosteroids, such as dexametha-
sone (DXM), in an animal model of ODS could be beneficial
by preventing the opening of BBB.8 However, the facts that
there is an opening of BBB in experimental ODS, that most
animals with an open BBB after a rapid correction of
hyponatremia will develop ODS, and finally that DEX could
be efficacious in ODS because it protects against the opening of
BBB, do not necessarily imply that an increase in the
permeability of BBB is the initial and priming pathogenic
phenomenon in this disorder. In fact, the exact role of this
increase in the permeability of BBB is still debatable, as it could
either represent the initial and crucial insult or simply a
surrogate, secondary marker in the course of the ODS; studies
addressing the relationship between BBB permeability and
ODS have not fully clarified this issue. Furthermore, the net
extent of protection conferred by DXM is controversial.8–11
Owing to the complex and mostly unknown nature of the
phenomenon that induces demyelinative lesions after rapid
correction of hyponatremia, few treatment options are
available, and there is no consensus on the appropriate
treatment strategy in ODS. Our group previously reported a
benefit in mortality and neurological manifestations due to
ODS, after a re-induction of hyponatremia up to 24 h after
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the initial correction in asymptomatic and pauci-sympto-
matic rats;12,13 the mechanisms underlying the beneficial
effect of serum sodium (SNa) re-lowering are poorly
understood and the action of this rescue treatment on BBB
and microglial activation has never been investigated.
In this work, we aimed at comparing DXM administration
and hyponatremia re-induction as preventive treatment
options in ODS. We further investigated BBB permeability
and microglial activation under both treatments in an
attempt to clarify the role of these two components in the
pathophysiology of ODS.
RESULTS
SNa values before and after correction of hyponatremia
We used a previously described animal model of ODS (See
Figure 1 for experimental protocol).8,14,15 Along with others,
we previously reported that a correction of hyponatremia
with a 24-h SNa gradient 425mEq/l was associated with a
high incidence of neurological damage.15 Therefore, to avoid
potential bias in survival because of inadequate correction
gradient, only rats that had severe hyponatremia (SNa
o120mEq/l) and that achieved an SNa gradient X25mEq/l
were included in the analysis.
Table 1 shows the SNa values in the three groups before
and after correction. SNa levels at day 4 were comparable in
all groups. In Group 3, the SNa gradient was re-lowered to a
mean value of 14mEq/l at the twenty-fourth hour, after a
mean gradient of 29mEq/l at the twelth hour.
Neurological manifestations and mortality after correction of
hyponatremia
Table 1 summarizes the outcome of the animals at day 5 (24 h
after correction) and at day 10 (5 days after correction).
At 24 h after correction of SNa, all rats became severely
symptomatic in Group 1; in Group 2, 50% of the animals
(8/16) were symptomatic; and in Group 3, only one animal
showed neurological signs. DXM administration resulted
in a significant reduction in neurological manifestations
(P¼ 0.01). However, animals treated with a re-induction of
hyponatremia showed a better clinical status. (P¼ 0.01,
Group 2 vs Group 3)
By day 10 of the experiment, all the rats treated with
hypertonic saline alone died (two rats were killed at day 7
because they were moribund). Only 3 of 16 rats treated with
DXM survived (P¼ 0.17 for DXM vs NaCl alone), and 15 of
16 rats survived in the group treated with SNa re-lowering.
(Po0.001 for SNa re-lowering vs NaCl alone and vs DXM).
Figure 2 shows the luxol fast blue staining of myelin in the
animals of each group.
IgG immunostaining
The extent and localization of BBB leakiness in the different
groups were analyzed on brain sections immunolabeled for
rat IgG. Representative microphotographs of IgG immuno-
staining carried out on brain slices are shown in Figure 3.
In animals treated with DXM or with a re-induction of
hyponatremia, only a faint immunostaining for IgG was
present around the blood vessels, whereas brain sections of
animals corrected with NaCl alone (Figure 3b) showed a
massive immunostaining for IgG.
BBB permeability
Blood–brain barrier permeability was quantitatively assessed
by Evans blue (EB) dye extravasation (Figure 4), as previously
described.16 The SNa values of the animals used for the EB
dye experiment are given in Table 2. As shown in Figure 4,
Group 1 : n = 12
Group 2 : n = 16
Group 3 : n = 16
Day 4
Correction  of hypoNa
induction of ODS
Day 0
Induction of hypoNa
Day 5
Final gradient
symptoms analysis
Day 10
Mortality analysis
4 days
DXM (2 mg/kg):
5 days
Re-lowering of SNa
12 h
0 h 6 h
Figure 1 | Schematic representation of the experimental protocol used. Hyponatremia was induced by a combination of DDAVP
infusion and liquid diet, and was maintained for 4 days. Correction was carried out using intraperitoneal hypertonic NaCl. Rats were allowed
to consume food at day 5 after blood sampling and to consume water at day 6. In Group 2, dexamethasone (DXM) was administered 0 and
6 h after correction, whereas in Group 3, serum sodium was re-lowered 12 h after correction. Symptoms and mortality were recorded 1 and
5 days (day 5 and 10, respectively) after correction of hyponatremia in the three groups. HypoNa, hyponatremia; ODS, osmotic
demyelination syndrome; SNa, serum sodium.
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BBB permeability was increased in rats as early as 12 h after
correction compared with that in uncorrected rats
(Po0.001), and this increased permeability persisted for
24 h after correction. Treatment with DXM or SNa re-
lowering resulted in a significant decrease in BBB perme-
ability 12 h after correction. At 24 h after correction,
treatments with DXM and re-induction of hyponatremia
had the same protective effect on BBB permeability (Po0.01
compared with rats treated with NaCl alone, P¼NS
compared with uncorrected control rats).
Immunostaining for microglial activation
Representative microphotographs of activated microglia
immunostaining are shown in Figure 5.
We confirmed the intense immunostaining observed in
rats corrected with NaCl alone, mostly in the hippocampus,
basal ganglia, and deep cortical areas (Figure 5b). In rats
treated with DXM (Figure 5c) or with a re-induction of
hyponatremia (Figure 5d), moderate immunostaining for
activated microglia was also observed.
DISCUSSION
In these experiments, we found that, compared with rats
treated with NaCl alone, rats treated with DXM presented
less neurological manifestations 24 h after correction of
chronic hyponatremia, but DXM failed to reduce the
mortality at 5 days; on the contrary, re-lowering of SNa
was efficacious in both reducing neurological manifestations
and mortality. We further investigated the opening of BBB
and microglial activation with the same treatments. We
confirmed the previous findings with regard to the increase in
BBB permeability and the protective effect of DXM on that
increase (5, 7, 8, and 9). This study also suggests for the first
time that a decrease in the permeability of BBB is associated
with SNa re-lowering after an inadvertent correction of
hyponatremia. As previously suggested,17 we found that
microglial activation occurs after correction of chronic
hyponatremia with hypertonic saline alone in the rat model
of ODS.
This study shows two important points: first of all, our
results suggest that re-induction of hyponatremia is more
efficient than DXM in the prevention of myelinolysis. This
finding has an obvious clinical importance. Previous papers
have reported a beneficial effect of corticosteroids in
experimental osmotic demyelination8–11 syndrome and iso-
lated cases reported have echoed these experimental find-
ings.18 In our study, however, although we confirmed an early
protection of DXM from neurological manifestations of
ODS, we showed, with a larger series of animals, that DXM
does not significantly impact mortality in this experimental
Table 1 | Serum sodium values (SNas) and clinical data in the three groups of rats measured before (day 4) and after (12 or
24 h) treatment, in the experiment addressing mortality
Group 1 NaCl alone
(n=12)
Group 2 NaCl+DXM
(n=16)
Group 3 NaCl+SNa re-lowering
(n=16)
SNa at day 4 (mEq/l) 108±2* 107±1* 104±2*
SNa 12 h after correction — — 133±2*,w
SNa at 24 h 137±2*,w 136±1*,w 117±2
d-SNa at 12 h — — 29±1*
d-SNa at 24 h 29±1* 29±1* 14±1
Neurological manifestations at day 5 12/12 8/16z 1/16z
Mortality at day 10 12/12 13/16y 1/16y
ANOVA, analysis of variance; DXM, dexamethasone; NaCl, hypertonic NaCl.
Data are presented as means±s.e.m.
*P=NS between the three groups.
wPo0.01 compared with SNa before the correction (day 4).
zP values: Group 1 vs Group 2, o0.01; Group 3 vs Group 2, o0.01; Group 3 vs Group 1, o0.001.
yP values: Group 1 vs Group 2, NS; Group 3 vs Group 2, o0.001; Group 3 vs Group 1, o0.001.
w2-test and one-way ANOVA were used for statistical analysis.
Figure 2 |Myelin staining (Luxol Fast Blue/Cresyl Violet).
Representative microphotographs of brain sections stained with
Luxol Fast Blue and Cresyl Violet for myelin. (a) Rats treated with
dexamethasone (2mg/kg body weight) at 0 and 6 h after the
correction. (b) Rats treated with re-induction of hyponatremia.
Rats treated with hypertonic saline alone (c) showed massive
cortical demyelinative lesions (arrows), characterized as zone of
pallor in the deep cortex, compared with uncorrected controls (d).
(a and d) At 5 days after correction of chronic hyponatremia.
(c) At 3 days after correction of chronic hyponatremia.
Bar¼ 200 mm. CC: corpus callosum.
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model. In contrast, SNa re-lowering was effective in
protecting from both neurological manifestations and death
in the animal model of ODS. These later findings are in
accordance with our previous experiments,12,13 and support
recent clinical evidence of the protective role of re-induction
of hyponatremia in the prevention of ODS in humans.19–21
Our experiments suggest that the efficacy of DXM in terms of
mortality should be considered with caution and that early
re-induction of hyponatremia is to be preferred if the patient
has been submitted to extensive correction of hyponatremia.
NaCl + DXM
NaCl alone
NaCl + re-induction of hyponatremia
Control
Figure 3 | Immunoreactivity for IgG in brain of rats of the four different groups. There is a significant increase in IgG reactivity in
the cortical and subcortical areas, and in the basal ganglia of rats treated with NaCl alone (arrows) compared with that in all other groups
(24 h after correction). DXM, dexamethasone.
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Figure 4 | Effect of the different treatments on blood–brain barrier (BBB) permeability after rapid correction of hyponatremia.
*Po0.01 in Group 1 vs Group 4 (uncorrected controls), and Po0.01 in Group 1 vs Group 2 (rats treated with NaCl alone and NaCl/DXM,
respectively) and Group 3 (treated with NaCl and re-induction of hyponatremia), both 12 and 24 h after correction of serum sodium (SNa).
P¼NS between groups 2, 3, and 4, 12 and 24 h after correction. One-way analysis of variance, followed by Bonferroni LSD, was used for
statistical analysis. BBB permeability was quantified using the Evans blue dye method 24 h after correction. Values are mean and s.e.m.
(n¼ 5–6 in each group). There is a striking increase in BBB permeability after rapid correction of hyponatremia. Treatment with DXM or SNa
re-lowering resulted in a decrease in the permeability of BBB. DXM, dexamethasone; SNa re k, serum sodium re-lowering.
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Some differences in experimental design and methodology
may account for the discordance between our results
and those of previously published experiments. In these
reports, particularly worrisome have been the end points
studied, the SNa gradient of animals included in the analysis,
and the sample size. The other experiments9–11 mostly
addressed the number or severity of lesions in the DXM-
treated group compared with that in the control group: some
reported10,11 a decrease in the number of demyelinative
lesions in rats treated with corticosteroids or in those that are
repeatedly tail transected compared with that in rats treated
with hypertonic saline alone, with no significant difference in
the number of affected animals (7 of 10 in tail transected and
8 of 10 in steroid treated vs 10 of 10 in control group).
Compared with previous papers, we used a larger number of
rats (n¼ 12–16) and we included in the analysis only rats
with a large increase of SNa (d-SNaX25mEq/l/day). By
choosing this set point of SNa gradient, we were more likely
to disclose any beneficial effect on mortality after treatment
with either DXM or hyponatremia re-induction, as such a
gradient is invariably associated with a high incidence of
neurological manifestations and death.15 In the previous
studies addressing this issue, animals had an SNa gradient of
o25mEq/l/day, which could explain the lower mortality rate
usually found and a possible overestimation of the protective
role of DXM.
The second key conclusion from our results is regarding
the role of BBB in ODS pathophysiology.
Some have hypothesized that the opening of BBB could
allow the passage of large blood-borne molecules (IgG and
complement) that could damage oligodendrocytes and
induce demyelination.5,6 In other animal models, as well as
in in vitro studies, osmotic opening of the BBB has been
shown to be involved in the transient modifications of
cellular cytoskeletal architecture, leading to a shrinkage of
tight junctions of endothelial cells.22–25 These changes have
been related to both the intensity and duration of the
osmotic stimulus and involve some proteins of the tight
junction complex, such as ZO 1, occluding, and claudin.22–24
In parallel, various inflammatory stimuli (cytokines and
nitric oxide) are known to regulate the permeability of BBB.26
Some of these inflammatory cytokines are shown to be
present in ODS.17 Taking into account the results of previous
experiments, we can hypothesize that the increase in the
permeability of BBB in ODS might involve two distinct but
overlapping components: one early, reversible osmotic
Table 2 | Serum sodium values (SNa) in the groups of rats used for EB analysis (data are presented as mean±s.e.m.)
12h After the correction of SNa 24 h After the correction of SNa Controls
Group 1: NaCl
alone (n=6)
Group 2:
NaCl+DXM
(n=6)
Group 1: NaCl
alone (n=5)
Group 2:
NaCl+DXM
(n=5)
Group 3: NaCl+SNa
re-lowering (n=5)
Group 4: uncorrected
controls (n=6)
SNa at day 0 (mEq/l) 106±1 104±1 102±2 104±2 102±2 104±1
SNa 12 h after correction 135±4 135±2 — — 131±1 —
SNa at 24 h 133±2 134±1 106±1 —
d-SNa at 12 h 30±2 31±2 — — 29±2 —
d-SNa at 24 h — — 31±2 30±2 4±2 —
DXM, dexamethasone; EB, Evans blue stain.
P=NS for SNa at day 4 between all groups; P=NS for SNa and dSNa at 12 h between all the compared groups; P=NS for SNa and dSNa at 24 h between Group 1 and Group 2;
Po0.001 for SNa at 24 h between Group 3 and Groups 1 and 2.
Figure 5 | Immunostaining for microglial activation. Representative microphotograph of activated microglia in the hippocampus of
rats of the four different groups. (a) Uncorrected controls. Massive immunoreactivity was observed in rats treated with NaCl alone (b), in rats
treated with dexamethasone (DXM) (c), and in those treated with re-induction of hyponatremia (d). On the right, a higher magnification of
the hippocampus of a rat treated with NaCl alone (e). Bar¼ 200 mm.
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component mediated by rapid changes in plasma tonicity
with the resultant mechanical shrinking of tight junctions of
the BBB and a late inflammatory component mediated by the
secretion of proinflammatory cytokines after propagation of
the osmotic insult.
The effect of DXM on BBB has been well characterized in
both in vivo and in vitro studies, and DXM has been shown to
modulate the changes in tight junctional proteins and other
components involved in the regulation of BBB physiology
with, as net effect, an increase in the stability of BBB.27,28
Regarding the re-lowering of SNa, we showed that the
permeability of BBB returned to near normal values after the
re-induction of hyponatremia; it is likely that the withdrawal
of the osmotic insult (by re-induction of hyponatremia) acts
on BBB by limiting the consequences of the inflammatory
processes triggered by a sustained osmotic stress.
Dexamethasone, to a similar extent as SNa re-lowering,
prevented the opening of the BBB observed after rapid
correction of SNa, but did not significantly affect mortality.
This suggests that the opening of the BBB component in ODS
is distinct from the initial demyelinative injury.
The hypothesis of the marginal contribution of the
opening of the BBB as the initial insult causing ODS is
further supported by other observations: first, the osmotic
opening of BBB has been extensively studied in the clinical
setting and has been shown to be transient,24,25,29 whereas all
papers studying this topic with respect to ODS reported a
long-lasting opening of the BBB, suggesting that the
increased permeability of BBB after 24 h is not related to a
mechanical osmotic phenomenon. Second, although lovas-
tatin has been shown to decrease the permeability of BBB in
various experimental settings, it has failed to show a
significant efficacy in ODS.17 Third, an increase in the
permeability of BBB has been well characterized in other
models of neurological injury; yet, such a specific pattern of
demyelination does not occur. These facts, when associated
with the results of our experiments, strongly imply that the
opening of BBB could count as a surrogate marker in ODS
resulting from the inflammatory milieu, which is distinct
from the priming insult.
We showed that rats could still develop ODS and die of it,
despite a closed BBB. However, neither our study nor the
previous one could fully decipher the exact role of BBB in
this disorder, and other experimental approaches are needed
to understand how the increased permeability of BBB
observed in ODS could be implicated in the complex
pathophysiology of this disorder.
In summary, although corticosteroids could decrease the
permeability of BBB and the neurological symptoms after
rapid correction of hyponatremia, this treatment does not
result in an increase in the overall survival rate in an
experimental model, suggesting that BBB permeability is
rather a surrogate marker of secondary phenomenon than
initial insult after rapid correction of chronic hyponatremia.
Our results are not readily transposable to human
practice, and it is important to stress on the fact that the
two treatment strategies compared in this study are clinically
different, because re-induction of SNa is a rescue maneuver,
whereas administration of DXM is strictly preventive.
Therefore, both the treatments can be combined for maximal
efficacy. Nevertheless, these experiments stress on the fact
that re-induction of hyponatremia is an efficacious treatment
option after an inadvertent correction of chronic hypona-
tremia.
Our experiments further show how complex the patho-
physiology of ODS is. Besides SNa re-lowering, the only
interventions that resulted in such a striking reduction in
mortality after rapid correction of chronic hyponatremia
were myoinositol30 administration and exogenous or en-
dogenous uremia.31,32 All these treatments affected the
organic osmolyte content of the brain. Indeed, important
variations in the organic osmolyte content in the brain have
been shown in chronic hyponatremia.33,34 These imbalances
in the ‘buffering potential’ of the cell could further lead to a
poor response to a rapid increase in the tonicity of
extracellular space, which could in turn trigger a cellular
lesion in oligodendrocytes with secondary inflammation,
finally leading to demyelination.
MATERIAL AND METHODS
Animals
Male Wistar rats (250–300 g) were used for all the experi-
ments. The animals were housed in individual cages under
conditions of constant temperature (23 1C) and a 12-h/12-h
light/dark cycle. They were allowed to adapt for 3–4 days and
were fed with standard pelleted chow with ad libitum access
to water before the beginning of the experiments. All
procedures were performed in accordance with guidelines
for animal care at Universite´ Libre de Bruxelles.
Induction of hyponatremia
In all animals, hyponatremia was induced by previously
described methods.8,14 In brief, an osmotic minipump
(Model 2001 Alzet, Palo alto, CA, USA) was filled with
desmopressin acetate (0.4 mg/ml) (Ferring, Sweden) and
inserted into the back of the animal, which was administered
light halothane anesthesia at the beginning of the experiment
(Day 0). On the day of the insertion, rats were switched to a
liquid diet with a low sodium content (AIN 76, Technilab
BMI, Someren, Netherlands). The liquid diet was maintained
for a total of 4 days.
Correction of hyponatremia
After 4 days of liquid feeding (day 4 of the experiment),
hyponatremia was rapidly corrected by administration of
NaCl 1M (2ml/100 g body weight) intraperitoneally in a
single dose. Desmopressin infusion was maintained all
through the experiment.
Pelleted chow was given to the animals on day 5 of the
experiment, after blood sampling, for the determination of
final 24-h SNa and to avoid incidental re-lowering occurring
at day 5; water was given only on day 6.
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Blood measurements
Blood samples (0.3ml) were collected by tail transection at days
0 and 1 after administering light anesthesia, for SNa analysis.
Electrolyte measurements were determined using MODULAR
p800 (Roche Diagnostics, Vilvoorde, Belgium).
Evaluation of neurological manifestations and mortality
In a first set of experiments (Figure 1), we addressed the effect
of DXM and SNa re-lowering in rats after rapid correction of
chronic hyponatremia in terms of neurological manifestations
and mortality. In these experiments, a total of 44 rats were
randomly assigned to three groups depending on the
treatment regimen. All groups were studied concurrently.
Group 1 (n¼ 12) consisted of hyponatremic rats, the SNa
of which was rapidly corrected with hypertonic saline
without further treatment.
Group 2 (n¼ 16) consisted of the DXM-treated group.
DXM (Aacidexam, Organon, Brussels, Belgium) was admi-
nistered subcutaneously at a dose of 2mg/kg body weight at
the time of correction of hyponatremia and 6 h later. This
administration scheme has been previously reported to be the
most protective in this setting.8
Group 3 (n¼ 16) consisted of hyponatremic rats corrected
with hypertonic saline, followed by re-induction of hypona-
tremia 12h later in asymptomatic rat. Blood samples were taken
for serum analysis, and only rats that achieved an SNa gradient
of correction X25mEq/l were treated with re-induction of
hyponatremia. Hyponatremia was re-induced by an intra-
peritoneal administration of water (10% of body weight) to
achieve a final SNa gradient p20mEq/l over 24h.12,13
Groups 1 and 2 included only rats with a 24-h SNa
gradient X25mEq/l. This value of SNa gradient has been
previously shown to be inevitably associated with brain
demyelinative lesions in animals corrected with NaCl alone.15
Animals were observed for neurological manifestations of
ODS 1 day and 5 days after correction of hyponatremia. Rats
were considered symptomatic if they showed one of the
following: slow or awkward gait, limb weakness and/or paralysis,
seizures, severe motor deficits, or a complete inability to move.
Immunohistochemistry
Animals were killed if they were found to be moribund in
their cages; otherwise, all surviving animals at day 10 of the
experiment (5 days after correction of chronic hyponatremia)
were killed by decapitation. Brain was divided into two
hemispheres and was fixed overnight in formalin (10%)
before rinsing with phosphate-buffered saline. Specimens
were then embedded in paraffin and cut into sagittal sections
of 7 mm thickness using a microtome.
Immunohistochemical detection of IgG was performed on
rat brain sections, as previously described.5 After deparaffi-
nation and rehydration of tissue sections, endogenous
peroxidases were blocked (0.3% H2O2 in methanol) and
non-specific binding of the antibody was inhibited using
appropriate species’ normal serum at 1/10 ratio. Slides were
then incubated with a biotinylated goat anti-rat IgG antibody
(1:100; Vector, Burlingame, CA, USA) for 3 h, followed by
avidin–biotin–peroxidase (Vector Labs, Labconsult, Brussels,
Belgium) and diaminobenzidine (Dako, Heverlee, Belgium).
Immunohistochemistry for activated microglia was per-
formed using a mouse anti-ED1 antibody16 (1/200, Serotec,
Dusseldorf, Germany), followed by a biotinylated horse anti-
mouse antibody (1:100; Vector).
Evaluation of BBB by EB dye extravasation
In a second set of experiments, EB was used to determine
BBB permeability at 12 and 24 h after correction of
hyponatremia in the different groups studied, as well as in
one group of uncorrected hyponatremic rats serving as
controls (Group 4).
In each animal, EB solution (Sigma Chemical, St Louis,
MO, USA) (2% in saline; 3ml/kg) was injected intravenously
24h after rapid correction of chronic hyponatremia and was
allowed to circulate for 40min. The chest was subsequently
opened and the brain was transcardially perfused with 100ml
of saline through the left ventricle at 100-mmHg pressure
until an almost colorless perfusion fluid was obtained from the
right atrium. Brains were then weighed and placed in 50%
trichloroacetic acid solution. After homogenization and
centrifugation,16 the absorbance of the supernatant was
analyzed spectrophotometrically at 610 nm and the content
of EB, expressed per gram of brain tissue, was calculated using
a linear standard curve derived from known amounts of dye.
Statistical analysis
Results were expressed as mean±s.e.m. The Mann–Whitney
nonparametric test, Fischer’s exact test on proportions, and
one-way analysis of variance followed by Bonferroni’s LSD
were used when appropriate. P valueso0.05 were considered
to be significant.
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